

Invega Sustenna® Quiz

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use?

Use inch 23G needle.

2. Name the most common side effects a patient may experience when taking Invega Sustenna®.

Injection site reactions, somnolence/sedation, dizziness, feeling restless, abnormal muscle movements including tremor, shuffling, uncontrolled involuntary movements and abnormal movements of your eyes.

3. What black box warning is associated with this medication?

Increased mortality in elderly patients with dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Invega Sustenna is not approved for use in patients with dementia-related psychosis.

4. What is the recommended initial dosage for a person with a creatinine clearance of 65mL/min? **The initial dose is 156mg.**

5. What would the recommended maintenance dosage be for patient in #4? **The recommended maintenance dose is 78mg.**

6. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®? **The reason for trial of oral paliperidone or injectable risperidone is to establish tolerability.**

7. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure. **Use hand sanitizer, wear gloves, use alcohol pad to clean injection site.**

8. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

To protect patient's right to consent to treatment with psychoactive medications and to comply with the requirements of the Texas Administrative Code, and the Texas Health and Safety Code relating to psychoactive medications with consent.

